Cynthia R. Osborne

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial

Joyce O’Shaughnessy, Cynthia R. Osborne, John Pippen et al. · Journal of Clinical Oncology · 2009 · 243 citations

Surgical Oncology, Breast Oncology, Tumoral Pathology +15

Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

David W. Craig, Joyce O’Shaughnessy, Jeffrey Kiefer et al. · Molecular Cancer Therapeutics · 2012 · 223 citations · Full text

Metastatic Tnbc, Breast Oncology, Engineering +15

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues

Songdong Meng, Debu Tripathy, Sanjay Shete et al. · Proceedings of the National Academy of Sciences · 2006 · 156 citations · Full text

Gene Amplification, Breast Oncology, Immunology +16

Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer

Jennifer R. Diamond, Carlos Becerra, Donald Richards et al. · Breast Cancer Research and Treatment · 2020 · 141 citations · Full text

Breast Oncology, Medicine, Anti-frizzled Antibody Vantictumab +6